RT @doctorRBC: Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic ⭐️ACR20, 50,70 response

Social Author Image
https://pbs.twimg.com/profile_images/1324821320429981703/dAiq_hpT.jpg
Tweet Author
doctorRBC
Social Author Name
Robert B Chao, MD
Tweet Content
Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic ⭐️ACR20, 50,70 response ⭐️significant resolution of enthesitis/dactylitis Abs#OP0228 #EULAR2021 @RheumNow
Show on Archive Page
On
Display in Search Results
On
PDQ
Off

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×